iPhot receives a 940K€ grant

Article

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

“The ultimate goal of the iPhot project is to optimize the process of adaptive-optics enabled retinal imaging in order to obtain morphological, quantitative and longitudinal information at the level of single photoreceptor cells in humans” notes Imagine Eyes' CEO Nicolas Chateau. Adding: “Clinical investigations related to this particular project will be focused on early detection of photoreceptor damage in cases of genetically or phenotypically defined inheritable retinal dystrophies. As the project and its technology advances, we plan to partner with additional clinical investigation sites to perform research on the healthy retina as well as other retinal diseases.”

“Unfortunately, most cases retinal of disease are diagnosed only once the patient has suffered significant, irreparable vision loss” says Pr. Michel Paques, iPhot's Project Coordinator, from the Quinze-Vingts hospital. “Functional testing detects visual impairment only once a significant proportion of cells have degenerated. More importantly, functional defects, and the associated morphological changes at the level of outer segments, can precede cell loss. The current imaging technologies that are used to diagnose and monitor the effectiveness of treatment lack the cellular level resolution needed to observe the retinal microstructures causing the visual dysfunction. The comprehensive analysis of the relationship between structural and functional parameters will guide both prognostic assessment and therapeutic decision making in affected patients. It should equally provide clues to discriminate and quantify irreversible versus reversible lesions.”

To view images obtained with Imagine Eyes' adaptive-optics retinal camera, click here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.